KR20120076706A - Whitening composition for external applications to the skin containing angelica keiskei koid. extracts - Google Patents

Abstract

PURPOSE: A whitening agent containing plant extract is provided to suppress tyrosinase activity and melanogenesis without side effect. CONSTITUTION: A cosmetic composition for skin whitening contains 0.001-10 wt% of Angelica extract powder as an active ingredient. A method for preparing the extract powder comprises: a step of extracting Angelica meal with C1-C6 alcohol or a mixture solvent of the alcohol and water; a step of concentrating the extract by precipitation, evaporation, decompression, ultrafiltration, reverse osmosis, and centrifugation; and a step of formulating the concentrate into powder. The Angelica meal is extracted using water, alcohol of 1-6 carbon numbers, acetone, ethyl acetate, n-hexane, diethyl ether, acetone, and benzene.

Description

Whitening composition for external applications to the skin containing Angelica Keiskei Koid. extracts}

Human skin color is determined by the amount of melanin, carotene, and hemoglobin, of which melanin is the most decisive factor. Melanin is produced from melanocytes, which are pigment cells present in the basal layer of the skin, and then transferred to surrounding keratinocytes to give a human skin color. If melanin is produced in excess, it is known to cause pigmentation such as spots and blemishes. The enzyme tyrosinase in melanocytes, an enzyme that plays a major role in melanin synthesis, is particularly activated by ultraviolet light. Therefore, when the sun receives a lot, the skin turns black. Accordingly, in the development of the cosmetic material of the skin lightening effect concept, most of the substances having inhibitory effects on tyrosinase activity have been targeted for screening. The present invention relates to melanin synthesis, which acts as the most important factor in pigmentation and blackening, and in detail, relates to whitening activity through inhibition of tyrosinase activity and inhibition of melanin synthesis.

The present invention relates to a skin whitening agent having an excellent skin whitening effect, and more particularly, to provide a skin whitening agent having an excellent whitening effect without side effects by containing an extract powder of Mt.

Human skin color is determined by the concentration and distribution of melanin pigments produced from melanocytes. The synthesis of melanin pigments is influenced by genetic, physiological and environmental factors related to hormone secretion, oxidative stress, and ultraviolet irradiation. Melanin, which is present in the outer skin of the human body, has a function of protecting the body from ultraviolet rays, but on the other hand, it is known that it is overproduced, not only forms spots and freckles, but also promotes skin aging and plays an important role in inducing skin cancer. have. Tyrosinase, such as ascorbic acid, kojic acid, arbutin, hydroquinone, glutathione or derivatives thereof, has been previously used to treat or reduce skin hyperpigmentation due to excessive melanin synthesis, pigmentation, spots, and freckles. Substances with inhibitory activity have been used in cosmetics and pharmaceuticals, but their use has been limited due to insufficient whitening effects, safety problems on the skin, formulation and stability problems when formulated in cosmetics, and the like. For example, some materials such as kojic acid and oil-soluble licorice extract have excellent whitening effect, but the usage is limited due to unsatisfactory storage stability over time, and thus there is a problem in that the whitening effect is limited. Therefore, there is a continuous search for a whitening active substance having excellent safety and excellent whitening activity. In this respect, plant natural products are not only excellent in safety but also have various beneficial ingredients for the human body, and thus are excellent targets for the whitening active substance. Efforts are being made to find plant natural products that have both a whitening effect and safety for human skin.

The present inventors searched for a new whitening agent having excellent whitening effect on plant natural products and at the same time safety for human skin, and found that the extract of Myeongil Leaf had excellent melanin synthesis as well as excellent safety for human skin. . Furthermore, the present inventors have found that the cosmetic composition for skin whitening has an excellent whitening effect when it contains the extract of Myeongil Leaf in an amount of 0.001 to 10% by weight, more preferably 0.01 to 5% by weight, based on the total weight of the composition. By completing the invention, it is to provide a skin whitening agent having an excellent whitening effect.

In order to achieve the above object, the skin lightening agent according to the present invention is characterized in that it contains the extract of Sunilyeonyeop as an active ingredient. In addition, it can be prepared a composition for skin whitening containing the extract of Myeongil-yeop above 0.001 to 10% by weight, more preferably 0.01 to 5% by weight relative to the total weight of the composition.

As described above, it is possible to manufacture a cosmetic for skin whitening containing the extract of Myeongyipyeon powder provided by the present invention, which shows a skin whitening effect through the control of tyrosinase activity without side effects on human skin.

[Figure 1]
1 is a result of the evaluation of the effect on the mushroom tyrosinase activity of the extract extract of Myeongil lobe according to the present invention.
[Figure 2]
2 is a result of the evaluation of the effect on the melanin synthesis of the B16F10 mouse melanoma cell line of the extract of Myeongil lobe according to the present invention.

The present invention relates to extracts utilizing the by-products of the solid components left over from the juice of the extract of Myeongil Leaf Green Juice in detail. (A) Myeongil leaf is composed of 1 to 6 carbon atoms and a mixed solvent of water Extracting with any one selected solvent; (b) concentrating the extract; (c) was prepared according to a method comprising formulating the concentrate into a powder.

In the step (a), Myeongil leaf can be extracted by a solvent extraction method known in the art. Examples of the extraction solvent include one selected from alcohols having 1 to 6 carbon atoms such as water, ethanol and methanol, organic solvents such as acetone, ethyl acetate, n-nucleic acid, diethyl ether, acetone, and benzene. A mixed solvent of can be used. Preferably it can be extracted with any one solvent selected from the group consisting of alcohol having 1 to 6 carbon atoms and a mixed solvent of water. In step (b), the extract is concentrated. It may be concentrated by a concentration apparatus or a concentration method known in the art and may be, for example, precipitation concentration, evaporation concentration, reduced pressure concentration, ultrafiltration, reverse osmosis, centrifugation. In step (c), the concentrate was formulated into a powder using a method such as lyophilization, spray drying, and dextrin inclusion. An extract powder prepared according to the above-described method is represented by a light leaf extract powder.

On the other hand, when using the extract extract Myeongilyeop according to the present invention for skin whitening cosmetics is preferably 0.001 to 20% by weight relative to the total weight of the composition. However, the quantity of the said light leaf extract powder is not specifically limited.

In addition, the cosmetic composition for skin whitening of the present invention preferably contains other whitening ingredients and the like which can give a synergistic effect to the whitening effect within the range that does not impair the whitening effect of the present invention, in addition to the extract of the day leaf. It is okay. Arbutin, an ascorbic acid derivative, etc. are mentioned as such a whitening component.

The whitening cosmetic of the present invention is not particularly limited in the formulation, for example, softening cream, astringent makeup, nourishing cream, nutrition cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing foam, cleansing water It can be formulated into cosmetics such as packs, powders, body lotions, body creams, body oils and body essences.

Example 1 Preparation of Myeongil Leaf Extract Powder

The raw material for extracting Myeongil-yeop was used as a by-product of the solid components left after the juice was prepared during the production of Myeongil-yeop green juice, and the extraction solvent was water, ethanol and methanol having 1 to 6 carbon atoms, such as acetone, ethyl acetate and n-nucleic acid. , Any one selected from organic solvents such as diethyl ether, acetone, benzene, or a mixed solvent thereof can be used. The extract was concentrated using a concentrator and concentration method known in the art, and the concentrate was powdered by lyophilization, spray drying, dextrin inclusion, and the like. However, the extraction and separation and purification method of the active ingredient is not necessarily limited to the above method.

Example 2 Assessment of Mushroom Tyrosinase Activity

Using the extract powder prepared in Example as a test substance, 0.06 mL of 0.3 mM tyrosine or DOPA was mixed with 0.6 mL of 0.25M phosphate buffer (pH6.8), and then incubated at 30 ° C. for 10 minutes by adding 1.9 mL of distilled water. 0.1 mL of sample is added and 0.1 mL of tyrosinase is added to react. The activity level was evaluated by dopachrome biosynthesized at 405nm wavelength. As shown in Figure 1, compared to the DMSO treatment group as a control material, the concentration-dependent mashrom tyrosinase at concentrations of 10, 15, 17, 27 and 35% at concentrations of 10, 25, 50, 100 and 200 ㎍ / ml It has been shown to inhibit the activity of. The values are expressed as mean ± S.D. Of three experiments. Asterisk (*) indicates a significant decrease compared to the control DMSO treatment (*: p <0.05, **: p <0.01).

Example 3 Evaluation of Melanin Inhibitory Activity Using B16-F10 Mouse Melanoma Cell Line

Using the extract powder prepared in Example as a test substance, put into 1 X 10 ⁶ cell / ml (final volume 3 ml) in a 6-well plate (melanin quantitative) with DMEM containing 10% FBS, 37 ℃, 10% CO2 Incubate for 24 hours in an incubator. After incubation, the medium is removed and the test material is added to DMEM medium and treated daily for 3 days. On day 5, the culture medium was removed from the 6-well plate and treated with 0.25% trypsin-EDTA (Sigma Chemical Co.) solution to recover the cell pellet, transferred to a 1.5 ml tube, and centrifuged at 12,000 rpm for 10 minutes to remove the supernatant. do. After drying the pellet obtained at 60 ℃ 100N of 1N NaOH to dissolve the intracellular melanin. Dilute this solution with PBS and measure the absorbance at ELISA reader 405 nm to determine the rate of inhibition of melanin production. Using the cells without the extract as a control, the whitening effect was measured by measuring the melanin production inhibition level of the test substance compared to the melanin content in the control group. According to Equation 1 below, the melanin production inhibition rate was calculated and the results are shown in FIG. As a result of examining the effect on the melanin production of B16-F10 mouse melanoma cell line using the extract of Myeongil foliar as a test substance as shown in FIG. 2 compared to the DMSO treatment group as a control, 10, 25, 50, 100, 200 ㎍ / ml It was shown to inhibit melanogenesis in a concentration-dependent manner at concentrations of 18, 28, 45, 50 and 64%, respectively. The values are expressed as mean ± SD of three experiments. Asterisk (*) means a significant decrease compared to the control DMSO treatment (*: p <0.05, **: p <0.01).

Equation 1

                              Absorbance of each test substance

Melanin production inhibition rate (%) = 100 (--------------------- X 100)

                                Absorbance of the Control

Example 4 Evaluation of Inhibitory Activity of Tyrosinase Activity Using B16-F10 Mouse Melanoma Cell Line

Using the extracted powder prepared as an example, DMEM containing 10% FBS was added to 2 X 10 ⁵ cell / ml (final volume 3 ml) in a 6-well plate (melanin quantitative). Incubate for 24 hours in an incubator. After incubation, the medium is removed and the test material is added to DMEM medium and treated daily for 3 days. On day 5, the culture medium was removed from the 6-well plate and treated with 0.25% trypsin-EDTA (Sigma Chemical Co.) solution to recover the cell pellet, and transferred to a 1.5 ml tube, and 200 μl of phosphate buffer (pH 6.8) was added. After centrifugation for 10 minutes at 10,000rpm. Collect the supernatant, put 150 μl of the solution into a 96-well microplate, and add 50 μl of 10 mM L-DOPA. After incubation at 37 ° C. for 30 minutes, the absorbance was measured at 405 nm in the amount of dopa chrome produced using a micro plate reader.

On the other hand, the formulation of the skin whitening cosmetic containing the extract of Myeongilyeop of the present invention can be arbitrarily selected, and can be prepared in various forms such as nutrition cream, nutrition lotion, massage cream, nutrition essence, supple cosmetics, which are conventional cosmetic formulations. have.

Cosmetics containing extract of Myeongil Leaf can be used safely without side effects on the skin, and also have excellent effects of inhibiting pigmentation by inhibiting tyrosinase activity and melanin production. Very effective for improvement and skin whitening.

*: p <0.05 **: p <0.01

Claims (3)

Skin whitening cosmetics containing extract of Myeongil Leaf as an active ingredient The skin whitening cosmetic according to claim 1, wherein the content of the extract of Myeongil Leaf is 0.001 to 10% by weight. The cosmetic powder for skin whitening according to claim 2, wherein the extract content of Myeonilyeop is 0.001 to 10% by weight.

Images